Why the study?
Does pretreatment with monoamine oxidase inhibitors, reserpine, or guanethidine alter the severity of isoprenaline-induced myocardial necrosis?
Does pretreatment with monoamine oxidase inhibitors, reserpine, or guanethidine alter the severity of isoprenaline-induced myocardial necrosis?
Answers are grounded in this paper and cite their sources.
Catecholamine levels play an important role in isoprenaline-induced myocardial necrosis, which is inhibited by MAO inhibitors and exacerbated by reserpine and guanethidine.
Isoprenaline hydrochloride in subcutaneous doses of 2 × 10 to 2 × 680 mg/kg caused histologically detectable, characteristic heart necroses. Pathological changes were dose-dependent. The degree of necrosis was assessed by a quantitative histological method based on counting the changed morphological elements. The heart necroses due to 2 × 40 mg/kg of isoprenaline were significantly inhibited by pretreatment with different monoamine oxidase inhibitors (iproniazid, a derivative of hydrazine and pargyline and E-250 of the non-hydrazine type, all at 7 × 50 mg/kg intraperitoneally); their severity was significantly increased by reserpine (7.5 mg/kg/48 hr subcutaneously) and guanethidine (2 × 30 mg/kg subcutaneously). In these effects an important role is attributed to respective changes in catecholamine levels.
No takes yet. Share an insight, caveat, or question.
Leszkovszky et al. (1967) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: